Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Adapted COVID-19 Vaccine (BNT162b2) among Older Adults in Emergency Departments in Japan
jRCT1030250121Suspended
- Sponsor
- TXP Medical
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by TXP Medical. Primary endpoint: COVID-19-associated hospitalization. Started Jun 2025; status: suspended.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1030250121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250121.